Genmab — September 2022
-
Some key opinion leaders (KOLs) in neurology have said in a recent FirstWord Therapy Trends report that they would be hesitant to prescribe a rapid-infusion therapy because of negative experiences in patients receiving Roche’s Ocrevus (ocrelizumab) in its two-hour, twice-yearly infusion time, approved by the FDA in 2020.
-
Aktiemarkedet kan ikke lide prisfaldet på olie- og gas.
-
Det går hårdt ud over aktierne i sektoren.
-
Ja, og olieprisen er nu under prisen den dag, hvor Rusland invaderede Ukraine.
-
USA/lukning: Stor kursfremgang - vækst i front efter rentefald
https://www.proinvestor.com/investornyt/876162/usa-lukning-stor-kursfremgang-vaekst-i-front-efter-rentefald -
Godmorgen.
-
Godmorgen.
-
Torsdagens aviser med Mærsk, Danske Bank og SAS https://www.proinvestor.com/investornyt/876279/torsdagens-aviser-med-maersk-danske-bank-og-sas
-
Aktier: Er investorerne klar til ECBs rentebombe? https://www.proinvestor.com/boards/106019
-
Kan aktiemarkedet overvinde både høje renter og recession? Gør dig klar til en lang række spændende emner, når vores to værter runder den forventede renteforhøjelse, gaspriserne og om aktiemarkedet har mistet sin grønne energi. https://www.proinvestor.com/boards/106020
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind